Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors

被引：28

作者：

Zhang, Long ^{[1
]}

Yang, Yingying ^{[1
]}

Zhou, Haojie ^{[1
]}

Zheng, Qingmei ^{[1
]}

Li, Yuhao ^{[1
]}

Zheng, Shansong ^{[1
]}

Zhao, Shuyong ^{[1
]}

Chen, Dong ^{[1
]}

Fan, Chuanwen ^{[1
]}

机构：

[1] Qilu Pharmaceut Co Ltd, Shandong Prov Key Lab Small Mol Targeted Drugs, Jinan 250100, Shandong, Peoples R China

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2015年 / 102卷

关键词：

Quinazoline derivatives; H1975; EGFR-T790M; HCC827; A-431; GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; IRREVERSIBLE INHIBITORS; EGFR INHIBITOR; ACQUIRED-RESISTANCE; T790M MUTATION; PHASE-II; GEFITINIB; 4-(PHENYLAMINO)QUINAZOLINE;

D O I：

10.1016/j.ejmech.2015.08.026

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We have developed a series of 6, 7-disubstituted-4-(arylamino) quinazoline derivatives that functioned as irreversible EGFR inhibitors, and these compounds exhibited excellent enzyme inhibition potency. As compared with afatinib, some of them showed significantly enhanced activities towards H1975 cells (EGFR-T790M). Furthermore, the optimized compounds 7q and 8f also demonstrated good pharmacokinetic profiles, oral bioavailability as well as excellent in vivo efficacy in H1975 and HCC827 xenografts at a non-toxic dose. Based on the improved safety and efficacy against EGFR-T790M resistance, 7q and 8f are promising candidates for further studies. (C) 2015 Elsevier Masson SAS. All rights reserved.

引用

收藏

页码：445 / 463

页数：19

相关论文

共 50 条

[21] The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations [J].

Yoshimura, Akihiro ;

Yamada, Tadaaki ;

Okura, Naoko ;

Takeda, Takayuki ;

Furutani, Wataru ;

Kubota, Yutaka ;

Shiotsu, Shinsuke ;

Hiranuma, Osamu ;

Nishioka, Naoya ;

Chihara, Yusuke ;

Tamiya, Nobuyo ;

Kaneko, Yoshiko ;

Uchino, Junji ;

Takayama, Koichi .

BMC CANCER, 2018, 18

[22] Discovery of novel 4-arylamino-quinazoline derivatives as EGFRL858R/T790M inhibitors with the potential to inhibit the non-small cell lung cancers [J].

Gan, Wenhui ;

Wang, Caolin ;

Pan, Qingshan ;

Li, Yuzhen ;

Guo, Yuping ;

Fan, Dang ;

Peng, Yuting ;

Rao, Zixuan ;

Xu, Shan ;

Zheng, Pengwu ;

Zhu, Wufu .

BIOORGANIC CHEMISTRY, 2022, 127

[23] Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M) [J].

Shaheen, Mennatallah A. ;

El-Emam, Ali A. ;

El-Gohary, Nadia S. .

BIOORGANIC CHEMISTRY, 2020, 105

[24] Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation [J].

Su, Zhicheng ;

Yang, Tingyuan ;

Wang, Jie ;

Lai, Mengzhen ;

Tong, Linjiang ;

Wumaier, Gulinuer ;

Chen, Zhuo ;

Li, Shengqing ;

Li, Honglin ;

Xie, Hua ;

Zhao, Zhenjiang .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (16)

[25] Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells [J].

Katayama, Yuki ;

Yamada, Tadaaki ;

Tokuda, Shinsaku ;

Okura, Naoko ;

Nishioka, Naoya ;

Morimoto, Kenji ;

Tanimura, Keiko ;

Morimoto, Yoshie ;

Iwasaku, Masahiro ;

Horinaka, Mano ;

Sakai, Toshiyuki ;

Kita, Kenji ;

Yano, Seiji ;

Takayama, Koichi .

CANCER MEDICINE, 2022, 11 (04) :944-955

[26] Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives [J].

Mowafy, Samar ;

Galanis, A. ;

Doctor, Zainab M. ;

Paranal, Raymond M. ;

Lasheen, Deena S. ;

Farag, Nahla A. ;

Janne, Pasi A. ;

Abouzid, Khaled A. M. .

BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (16) :3501-3512

[27] Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer [J].

Kim, Dong Ha ;

Choi, Yun Jung ;

Kim, Seon Ye ;

Lee, Jung-Eun ;

Sung, Ki Jung ;

Sung, Young Hoon ;

Kim, Woo Sung ;

Kim, Sung-Eun ;

Ryu, Hyung Chul ;

Kim, Jae Sun ;

Lu Guangying ;

Choi, Chang-Min ;

Rho, Jin Kyung ;

Lee, Jae Cheol .

TARGETED ONCOLOGY, 2018, 13 (03) :389-398

[28] Structure-activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy [J].

Zhuo, Lin-Sheng ;

Wu, Feng-Xu ;

Wang, Ming-Shu ;

Xu, Hong-Chuang ;

Yang, Fan-Peng ;

Tian, Yan-Guang ;

Zhao, Xing-E ;

Ming, Zhi-Hui ;

Zhu, Xiao-Lei ;

Hao, Ge-Fei ;

Huang, Wei .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 208

[29] Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors [J].

Song, Zhendong ;

Jin, Yue ;

Ge, Yang ;

Wang, Changyuan ;

Zhang, Jianbin ;

Tang, Zeyao ;

Peng, Jinyong ;

Liu, Kexin ;

Li, Yanxia ;

Ma, Xiaodong .

BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (21) :5505-5512

[30] Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment [J].

Wang, Cheng ;

Wang, Xin ;

Huang, Zhi ;

Wang, Tianqi ;

Nie, Yongwei ;

Yang, Shengyong ;

Xiang, Rong ;

Fan, Yan .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 237

← 1 2 3 4 5 →